potassium phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4527 7778-53-2

Description:

MoleculeDescription

Synonyms:

  • potassium phosphate
  • tripotassium phosphate
  • potassium orthophosphate
used in dental materials and to treat hypophosphatemia; RN given refers to cpd with unspecified MF
  • Molecular weight: 212.27
  • Formula: K3O4P
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 86.25
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Encephalopathy 51.73 39.69 17 584 46427 90581419

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 57.82 33.35 20 389 44507 42576419
Toxic epidermal necrolysis 50.68 33.35 16 393 26734 42594192

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 81.90 30.37 30 1145 70276 110517848
Encephalopathy 40.79 30.37 19 1156 81036 110507088
Toxic epidermal necrolysis 37.17 30.37 16 1159 56711 110531413
Myocardial reperfusion injury 35.44 30.37 5 1170 140 110587984

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B05XA06 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
I.V. SOLUTION ADDITIVES
Electrolyte solutions
MeSH PA D002021 Buffers
MeSH PA D002327 Cariostatic Agents
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:33287 fertilizers

Related Drugs by ATC class:

B05XA Electrolyte solutions 18 drugs
ammonium chloridecalcium chloridecalcium gluconatehydrochloric acidmagnesium chloridemagnesium phosphatemagnesium sulfatepotassium acetatepotassium chloridepotassium lactatesodium acetatesodium bicarbonate show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypophosphatemia off-label use 4996001
Calcium renal calculus off-label use 427649000
Anuria contraindication 2472002 DOID:2983
Hypocalcemia contraindication 5291005
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Cirrhosis of liver contraindication 19943007 DOID:5082
Hyperphosphatemia contraindication 20165001 DOID:0050459
Sarcoidosis contraindication 31541009 DOID:11335
Hypernatremia contraindication 39355002
Body fluid retention contraindication 43498006
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Heart disease contraindication 56265001 DOID:114
Congenital myotonia, autosomal dominant form contraindication 57938005
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Oliguria contraindication 83128009
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Hyporeninemic hypoaldosteronism contraindication 236464008
Edema contraindication 267038008
Azotemia contraindication 445009001
Severe dehydration contraindication 450316000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML) POTASSIUM PHOSPHATES CMP DEV LLC N212121 Sept. 19, 2019 DISCN SOLUTION INTRAVENOUS 10632150 April 19, 2039 POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
1.18GM/100ML (11.8MG/ML);1.12GM/100ML (11.2MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11813291 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
1.18GM/100ML (11.8MG/ML);1.12GM/100ML (11.2MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11925661 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11813291 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11925661 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019977 VUID
N0000148061 NUI
4017712 VANDF
4019977 VANDF
CHEBI:63036 CHEBI
CHEMBL4298074 ChEMBL_ID
C013216 MESH_SUPPLEMENTAL_RECORD_UI
DB09413 DRUGBANK_ID
34322 RXNORM
1859 MMSL
5337 MMSL
d03790 MMSL
000769 NDDF
421392008 SNOMEDCT_US
80916004 SNOMEDCT_US
C0071778 UMLSCUI
516951 PUBCHEM_CID

Pharmaceutical products:

None